Axovant Sciences Ltd (NASDAQ:AXON) traded up 7.3% on Thursday . The stock traded as high as $1.78 and last traded at $1.77. 621,025 shares were traded during mid-day trading, a decline of 74% from the average session volume of 2,402,244 shares. The stock had previously closed at $1.65.
AXON has been the topic of several recent analyst reports. Zacks Investment Research cut Axovant Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th. Oppenheimer restated a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 11th. BidaskClub cut Axovant Sciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 8th. ValuEngine upgraded Axovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Cowen restated a “hold” rating on shares of Axovant Sciences in a research note on Thursday, September 20th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. Axovant Sciences currently has an average rating of “Hold” and a consensus price target of $4.56.
The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 1.68.
Axovant Sciences Company Profile (NASDAQ:AXON)
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Featured Story: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.